221 related articles for article (PubMed ID: 34435672)
41. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
42. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
Liu KL; Tsai WC; Lee CH
PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
[TBL] [Abstract][Full Text] [Related]
43. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
44. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
45. Clinical Outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome.
Levy Yurkovski I; Rokach L; Melamed G; Alapi H; Gazit S; Patalon T; Tadmor T
Acta Haematol; 2023; 146(6):496-503. PubMed ID: 37517402
[TBL] [Abstract][Full Text] [Related]
46. Mycosis fungoides.
Zinzani PL; Ferreri AJ; Cerroni L
Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
[TBL] [Abstract][Full Text] [Related]
47. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
48. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
[TBL] [Abstract][Full Text] [Related]
49. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
50. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
51. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.
Blaizot R; Ouattara E; Fauconneau A; Beylot-Barry M; Pham-Ledard A
Br J Dermatol; 2018 Dec; 179(6):1322-1328. PubMed ID: 30098016
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
[TBL] [Abstract][Full Text] [Related]
53. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
54. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
55. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
Benner MF; Jansen PM; Vermeer MH; Willemze R
Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
[TBL] [Abstract][Full Text] [Related]
57. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis.
Giberson M; Mourad A; Gniadecki R
Dermatology; 2017; 233(4):320-325. PubMed ID: 29169156
[TBL] [Abstract][Full Text] [Related]
58. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
59. Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil.
Deonizio JM; Ascef RD; Sanches JA
Int J Dermatol; 2016 May; 55(5):e256-61. PubMed ID: 26711732
[TBL] [Abstract][Full Text] [Related]
60. How I treat mycosis fungoides and Sézary syndrome.
Prince HM; Whittaker S; Hoppe RT
Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
